INBX’s INBRX-106 plus pembrolizumab shows superior HNSCC efficacy vs pembrolizumab
INBRX-106, a hexavalent OX40 agonist, showed superior efficacy to pembrolizumab alone in first-line recurrent/metastatic HNSCC, especially in HPV+ patients, with higher response rates and improved progression-free survival and a favorable safety profile.